Ten Covid-19 vaccines could be available by the middle of 2021 if they win regulatory approval, but their inventors need patent protection, the head of the global pharmaceutical industry group said.
Despite the constant need for social distancing, mask-wearing and the isolation and economic uncertainty that resulted from the Covid-19 outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
AstraZeneca is likely to run an additional global trial to assess the efficacy of the company’s Covid-19 vaccine using a lower dosage, the British drugmaker’s chief executive was quoted as saying amid questions over the results of a late-stage study.
AstraZeneca said on Monday the company’s Covid-19 vaccine could be as much as 90% effective, giving the world’s fight against the global pandemic a new weapon, cheaper to make, easier to distribute and faster to scale-up than rivals.
AstraZeneca started late-stage trials of an experimental long-acting monoclonal antibody combination drug the company hopes could be used as a so-called prophylactic to prevent Covid-19 infection in at-risk people for up to 12 months.
Pfizer Inc. applied to U.S. health regulators for emergency use authorization (EUA) of the company’s Covid-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.
A roundup of some of the latest scientific studies on the novel coronavirus includes research on whether a childhood vaccine may help prevent severe Covid-19 and whether cigarette smoke increases cell vulnerability to Covid-19.
U.S. and European regulators could approve Pfizer and BioNTech’s experimental Covid-19 vaccine as early as mid-December, the German firm’s chief executive said, following the release of positive trial results.
BioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.
An AstraZeneca executive said he felt encouraged by “incredibly promising” large-scale Covid-19 vaccine trial results unveiled by New York-based Pfizer and the company’s German partner BioNTech.